연구동향 분석

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

Kim Dae-Seok Camacho Cristel V. Kraus W. Lee 2021년

논문상세정보
    • 저자 Kim Dae-Seok Camacho Cristel V. Kraus W. Lee
    • 제어번호 107245908
    • 학술지명 Experimental and molecular medicine
    • 권호사항 Vol. 53 No. - [ 2021 ]
    • 발행처 생화학분자생물학회
    • 자료유형 학술저널
    • 수록면 1-10
    • 언어 English
    • 출판년도 2021
    • 등재정보 KCI등재
    • 판매처
    유사주제 논문( 0)
인용/피인용

' Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance' 의 참고문헌

  • miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors
    Moskwa, P. [2011]
  • Use of poly ADP-ribose polymerase [PARP]inhibitors in cancer cells bearing DDR defects : the rationale for their inclusion in the clinic
    Cerrato, A. [2016]
  • Upregulation of poly(ADP-ribose)polymerase-1(PARP1)in triple-negative breast cancer and other primary human tumor types
  • Trapping of PARP1 and PARP2 by clinical PARP inhibitors
    Murai, J. [2012]
  • The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
  • The kinase polypharmacology landscape of clinical PARP inhibitors
  • The involvement of poly(ADP-ribose)polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea
  • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Farmer, H. [2005]
  • Structure of the catalytic fragment of poly(AD-ribose)polymerase from chicken
    Ruf, A. [1996]
  • Structural basis for potency and promiscuity in poly(ADPribose)polymerase(PARP)and tankyrase inhibitors
  • Structural basis for allosteric PARP-1 retention on DNA breaks
  • Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
    Murai, J. [2014]
  • Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
    Johnson, N. [2013]
  • Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase
  • Specific binding of snoRNAs to PARP-1promotes NAD(+)-dependent catalytic activation
    Huang, D. [2020]
  • Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality
    Gogola, E. [2019]
  • Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma
  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma(ARIEL2 Part 1) : an international, multicentre, open-label, phase 2 trial
    Swisher EM [2017]
  • Role of poly(ADP-ribose) formation in DNA repair
  • Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers
  • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
  • Resistance to therapy caused by intragenic deletion in BRCA2
  • Rescue of arrested replication forks by homologous recombination
    Michel, B. [2001]
  • Replication fork stability confers chemoresistance in BRCA-deficient cells
  • Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets
  • Poly(ADPribose) polymerase auto-modification and interaction with DNA: electron microscopic visualization
  • Poly(ADP-ribosylation) in vitro. Reaction parameters and enzyme mechanism
  • Poly(ADP-ribosyl)ation by PARP-1 : ‘PARlaying’ NAD+ into a nuclear signal
    Kim, M. Y. [2005]
  • Poly(ADP-ribose)polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
    Zaremba, T. [2009]
  • Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer
    Choi, Y. E. [2016]
  • Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress
    Tapodi, A. [2005]
  • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose)polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer
    Kaye, S. B. [2012]
  • Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
    Gray, H. J. [2018]
  • Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
    Nishio, S. [2017]
  • Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells
    Teng, P. N. [2015]
  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
  • PARPs and ADP-ribosylation in RNA biology : from RNA expression and processing to protein translation and proteostasis
    Kim, D. S. [2020]
  • PARP trapping beyond homologous recombination and platinum sensitivity in cancers
    Murai, J. [2019]
  • PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
  • PARP inhibitors: clinical utility and possibilities of overcoming resistance
  • PARP inhibitors in gynecologic cancers: what is the next big development?
  • PARP inhibitors : synthetic lethality in the clinic
    Lord CJ [2017]
  • PARP inhibitors : extending benefit beyond BRCA-mutant cancers
  • PARP inhibitor treatment in ovarian and breast cancer
    Weil, M. K. [2011]
  • PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells
  • PARP and PARG inhibitors in cancer treatment
    Slade, D. [2020]
  • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
    Kaufman, B. [2015]
  • Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
  • Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
  • Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme
    Chambon, P. [1963]
  • Modulation of chromatin superstructure induced by poly(ADP-ribose)synthesis and degradation
  • Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
  • Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
  • Mechanism for synthetic lethality in BRCA-deficient cancers : no longer lagging behind
  • Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
    Moore, K. [2018]
  • Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
  • Laying a trap to kill cancer cells:PARP inhibitors and their mechanisms of action
    Pommier, Y. [2016]
  • Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers
    Fong, P. C. [2009]
  • Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer
    Chen, C. C. [2018]
  • High speed of fork progression induces DNA replication stress and genomic instability
  • High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
  • Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
    Bajrami, I. [2014]
  • Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
  • EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
  • Does the ribosome translate cancer?
    Ruggero, D. [2003]
  • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
    Jiang, X. [2019]
  • Characterization of polymers of adenosine diphosphate ribose generated in vitro and in vivo
  • Characterization of poly(ADP-ribose)-histone H1 complex formation in purified polynucleosomes and chromatin
  • CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
    Xu, H. [2017]
  • Blocking c-Met-mediated PARP1 phosphorylation enhances antitumor effects of PARP inhibitors
    Du, Y. [2016]
  • BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance
  • BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance
    Drost, R. [2011]
  • Adenosine diphosphate ribosylation of histone H1 by purified calf thymus polyadenosine diphosphate ribose polymerase
    Okazaki, H. [1980]
  • Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21
    Kim, D. S. [2019]
  • Ablation of PARP-1does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
    Yang, Y. G. [2004]
  • A targeting modality for destruction of RNA polymerase I that possesses anticancer activity
  • 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks